Ali Ashraf Salah Ahmed

Dr. Ali Ashraf Salah Ahmed

Minia University, Minya, Egypt
orcid

Research Focus & Metrics

Academic Career Length

5Years (2022-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
14 September 2022 in Journal of Foot and Ankle Research
Verified
Journal Article
Open access
PDF file
YMYasmine Adel Mohamed
Yasmine Adel Mohamed
HFHossam Khaled Farouk
Hossam Khaled Farouk
MGMohamed Ibrahim Gbreel
Mohamed Ibrahim Gbreel
AAAbdelrahman Mahmoud Ali
Abdelrahman Mahmoud Ali
Ali Ashraf Salah AhmedAli Ashraf Salah Ahmed
Ali Ashraf Salah Ahmed
MGMohamed Mahmoud Abd‐El Gawad
Mohamed Mahmoud Abd‐El Gawad
Background: Diabetic foot ulcer (DFU) is one of the most serious diabetic complications. DFU is an open wound that usually occurs in the foot sole due to poor blood glucose control, peripheral neuropathy, and poor circulation. The human amniotic allograft membrane is a biological wound dressing derived from the amniotic membrane. It contains amino acids, nutrients, cytokines, and growth factors that make the growth process easier.Objective: To compare dehydrated human amnion and chorion allograft (DHACA) plus the standard of wound care (SOC) with the SOC alone.Methods: We searched for randomized clinical trials (RCTs) on PubMed, Scopus, Cochrane, and Web of Science till April 2021 using relevant keywords. All search results were screened for eligibility. We extracted the data from the included trials and pooled them as mean difference (MD) or risk ratio (RR) with the 95% confidence interval (CI) using Review Manager software (ver. 5.4).Results: The pooled effect estimate from 11 RCTs showed that DHACA was superior to SOC regarding the complete wound healing in both 6th and 12th week (RR = 3.78; 95% CI: [2.51, 5.70]; P < 0.00001) and (RR = 2.00; 95% CI: [1.67, 2.39], P < 0.00001 respectively). Also, the analysis favored the DHACA regarding the mean time to heal in the 12th‐week (MD = ‐12.07, 95%CI: [‐19.23, ‐4.91], P = 0.001). The wound size reduction was better with DHACA (MD = 1.18, 95%CI: [‐0,10, 2.26], P = 0.03).Conclusion: Using DHACA with SOC is safer and more effective than using SOC alone for DFU patients.

4 October 2022 in Nutrients
Verified
Journal Article
Open access
PDF file
AMAbdelrahman Mahmoud
Abdelrahman Mahmoud
MAMohamed Abuelazm
Mohamed Abuelazm
Ali Ashraf Salah AhmedAli Ashraf Salah Ahmed
Ali Ashraf Salah Ahmed
HAHassan Abdalshafy
Hassan Abdalshafy
Basel AbdelazeemBasel Abdelazeem
Basel Abdelazeem
James Robert BrasicJames Robert Brasic
James Robert Brasic
Helicobacter pylori (H. pylori) is the most prevalent etiology of gastritis worldwide. H. pylori management depends mainly on antibiotics, especially the triple therapy formed of clarithromycin, amoxicillin, and proton pump inhibitors. Lately, many antibiotic-resistant strains have emerged, leading to a decrease in the eradication rates of H. pylori. Polaprezinc (PZN), a mucosal protective zinc-L-carnosine complex, may be a non-antibiotic agent to treat H. pylori without the risk of resistance. We performed a systematic review and meta-analysis to evaluate the efficacy and safety of a PZN-based regimen for the eradication of H. pylori. This study used a systematic review and meta-analysis synthesizing randomized controlled trials (RCTs) from WOS, SCOPUS, EMBASE, PubMed, and Google Scholar until 25 July 2022. We used the odds ratio (OR) for dichotomous outcomes presented with the corresponding 95% confidence interval (CI). We registered our protocol in PROSPERO with ID: CRD42022349231. We included 3 trials with a total of 396 participants who were randomized to either PZN plus triple therapy (n = 199) or triple therapy alone (control) (n = 197). Pooled OR found a statistical difference favoring the PZN arm in the intention to treat and per protocol H. pylori eradication rates (OR: 2.01 with 95% CI [1.27, 3.21], p = 0.003) and (OR: 2.65 with 95% CI [1.55, 4.54], p = 0.0004), respectively. We found no statistical difference between the two groups regarding the total adverse events (OR: 1.06 with 95% CI [0.55, 2.06], p = 0.85). PZN, when added to the triple therapy, yielded a better effect concerning the eradication rates of H. pylori with no difference in adverse event rates, and thus can be considered a valuable adjuvant for the management of H. pylori. However, the evidence is still scarce, and larger trials are needed to confirm or refute our findings.

4 November 2022 in Current Medical Research and Opinion
Verified
Journal Article
Closed access
AMAbdelrahman Mahmoud
Abdelrahman Mahmoud
Ali Ashraf Salah AhmedAli Ashraf Salah Ahmed
Ali Ashraf Salah Ahmed
MEMahmoud Elshinawy
Mahmoud Elshinawy
TAToka Ashour
Toka Ashour
MAMohamed Abugdida
Mohamed Abugdida
Basel AbdelazeemBasel Abdelazeem
Basel Abdelazeem
Post-orthopaedic operative pain is a serious concern that often requires the administration of analgesics; however, the optimal time of analgesic administration is still inconclusive. Perioperative...